Therapeutic Area: Urology

Primary Hyperoxaluria (NovoDetect)

This program offers seamless, no-charge genetic testing, primary hyperoxaluria (PH)–specific metabolite testing, and optional genetic counseling to help you identify the genetic cause of your patient’s kidney stones and provide clarity to guide your next steps.

Disease/Condition(s): primary hyperoxaluria (PH), Recurrent Kidney Stones (RKS)

Program Sponsor

Participating Lab

Primary Hyperoxaluria Type 1 (PH1) – Alnylam Act®

Alnylam Act® is a sponsored, no-charge genetic testing and counseling program for patients with a family history or suspected diagnosis of PH1. The Alnylam Act® program was created to provide access to genetic testing and counseling to patients as a way to help people make more informed decisions about their health.

– While Alnylam provides financial support for this program, tests and services are performed by independent third parties.
– Healthcare professionals must confirm that patients meet certain criteria to use the program.
– Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient-identifiable information. Alnylam may use healthcare professional contact information for research purposes.
– Both genetic testing and genetic counseling are available in the US and Canada.
– Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam product.
– No patients, healthcare professionals, or payers, including government payers, are billed for this program.

Disease/Condition(s): Primary Hyperoxaluria Type 1 (PH1)